Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

HSV-1 exploits immune system receptor to boost infectivity and cause disease

HSV-1 exploits immune system receptor to boost infectivity and cause disease

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals expands ophthalmology portfolio

Experts and patients share tips on preventing skin cancer

Experts and patients share tips on preventing skin cancer

Data on PV-10 combination therapy presented at AACR Annual Meeting

Data on PV-10 combination therapy presented at AACR Annual Meeting

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor signs research agreement to discover drug candidates to treat neglected diseases

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X advances ARGX-112 into formal preclinical development

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Mental health risk increased in children with atopic dermatitis

Mental health risk increased in children with atopic dermatitis

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

New insight into eczema’s itch

New insight into eczema’s itch

Asthma linked to atopic dermatitis persistence

Asthma linked to atopic dermatitis persistence

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting